COMMUNIQUÉS West-GlobeNewswire

Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease
21/01/2019
Compound Showed Marked Improvement Over Cenicriviroc VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: [...]
FocusCura subsidiary Luscii will continue as independent company with partner OMRON Healthcare to accelerate their international expansion
21/01/2019
Joining forces supports hospitals in moving care towards the home AMSTERDAM, The Netherlands, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Luscii, the e-health application for remote monitoring developed by FocusCura, is set to [...]
Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology
21/01/2019
Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) [...]
Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled
21/01/2019
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the board of directors of the Company has resolved to cancel the extraordinary general meeting which was to be held 25 January 2019. [...]
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
20/01/2019
ALPHARETTA, Ga., Jan. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Media Advisory: Top Smoking Cessation Experts Meet in Ottawa
19/01/2019
OTTAWA, Jan. 19, 2019 (GLOBE NEWSWIRE) -- National and international smoking cessation authorities are gathering in Ottawa today to attend the second and final day of the 11 th Annual Ottawa Conference: State of the Art [...]
Avis aux médias : Les plus grands experts de l’abandon du tabac se rassemblent à Ottawa
19/01/2019
OTTAWA, 19 janv. 2019 (GLOBE NEWSWIRE) -- Des experts du Canada et du monde entier se rassemblent à Ottawa aujourd’hui pour la deuxième et dernière journée de la 11 e Conférence annuelle d’Ottawa : Approches cliniques [...]
Les animaux de Taconic Biosciences effectuent la dernière mission à la Station spatiale internationale
18/01/2019
RENSSELAER, New York, 18 janv. 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, chef de file mondial dans la fourniture de modèles de rongeurs génétiquement modifiés, annonce l'achèvement d'une récente mission à la Station [...]
iKang Announces Completion of Going Private Transaction
18/01/2019
BEIJING, Jan. 18, 2019 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced [...]
MPX Receives Final Court Approval for Arrangement with iAnthus
18/01/2019
NEW YORK and TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“ iAnthus ” or the “ Company ”), (CSE: IAN , OTCQB: ITHUF) and MPX Bioceutical Corporation (“ MPX ”) (CSE: MPX; OTC: MPXEF) are [...]
Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market
18/01/2019
HOUSTON, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio [...]
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock
18/01/2019
NEW YORK, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology [...]
VitalHub Announces Closing of Strategic Private Placement with Industry Leaders
18/01/2019
TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSXV: VHI) is pleased to announce that it has completed a non-brokered private placement (the “Offering”) of units (“Units”) with the former [...]
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
18/01/2019
– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer – – Analysis of a previously conducted, randomized Phase 3 trial reveals patients with lymph [...]
NUSCULPT Opens New Practice in Cincinnati, OH Area
18/01/2019
This location provides patients with advanced body sculpting treatments and other cosmetic services CINCINNATI, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Unveiling the opening of a new practice in Crestview Hills, KY, just [...]
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany
18/01/2019
Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented TEL AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention [...]
Coherus BioSciences Announces New Employment Inducement Grants
18/01/2019
REDWOOD CITY, Calif., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 17, 2019, the compensation committee of the company’s board of directors granted [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
18/01/2019
FIT Biotech Oy Company release January 18, 2019 at 04:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]
Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz
18/01/2019
MINNEAPOLIS, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its chief executive officer and director, Carl Schwartz, has made an [...]

Pages